Headline RoundupJanuary 29th, 2021

Johnson & Johnson Announces 1-Shot Vaccine is 66% Effective Against Moderate to Severe COVID-19

Summary from the AllSides News Team

Johnson & Johnson announced Friday that its coronavirus vaccine, the only single-dose vaccine to pass phase 3 clinical trials, was on average 66% effective against moderate to severe illness, 85% effective against severe infections and 100% effective against hospitalizations and death. Effectiveness varied regionally, however; effectiveness against moderate illness was 72% in the U.S., 66% in Latin America and just 57% in South Africa, where a new and highly contagious strain of the virus is spreading. If approved by the FDA, Johnson & Johnson’s vaccine will be the fifth clinically-approved vaccine in circulation following Novavax’s recently-announced vaccine. Coverage on all sides compared the new vaccine to currently available ones and focused on the potential threat of new vaccine-resistant virus strains. Left- and center-rated outlets were more likely to include that the vaccine was developed by Johnson & Johnson’s Belgium-based subsidiary, Janssen Pharmaceuticals.

Featured Coverage of this Story

More headline roundups

AllSides Picks

More News about Coronavirus from the Left, Center and Right

From the Left

From the Center

From the Right